Merck says experimental skin disease drug meets main goal in mid-stage study

By Reuters News

- Merck MRK.N said on Wednesday its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps, abscesses and scarring.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk